Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

ETS1 is a key transcription factor that drives RANKL-expressing, tissue-destructive fibroblasts

Tissue-destructive fibroblasts in arthritis are driven by the transcription factor ETS1. Analysis of a cross-tissue, single-cell fibroblast dataset and genetic loss-of-function approaches further suggest that ETS1-expressing fibroblasts have a universal role in pathological tissue remodeling in multiple diseases, including arthritis, colitis and cancer.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: ETS1 activates RANKL-expressing destructive fibroblasts.


  1. Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246–251 (2019). This article shows that lining-layer THY1 fibroblasts induce bone and cartilage damage, whereas sublining-layer THY1+ fibroblasts promote inflammation.

    CAS  Article  Google Scholar 

  2. Takeuchi, T. et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (denosumab) in patients with rheumatoid arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann. Rheum. Dis. 75, 983–990 (2016). This multicenter, randomized, placebo-controlled phase 2 study shows that the addition of denosumab (monoclonal antibody to RANKL) to methotrexate treatment has the potential to suppress bone erosion in patients with RA.

    CAS  Article  Google Scholar 

  3. Buechler, M. B. et al. Cross-tissue organization of the fibroblast lineage. Nature 593, 575–579 (2021). This paper presents a cross-tissue, single-cell atlas of fibroblasts from healthy and perturbed tissues and reveals the organizing principles of fibroblast lineage within and across organs.

    CAS  Article  Google Scholar 

  4. Korsunsky, I. et al. Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases. Med 3, 1–38 (2022). This paper reveals shared pro-inflammatory fibroblasts across four chronic inflammatory diseases.

    Article  Google Scholar 

  5. Wohlfahrt, T. et al. PU.1 controls fibroblast polarization and tissue fibrosis. Nature 566, 344–349 (2019). This paper presents a role for PU.1 in fibroblasts for driving tissue fibrosis.

    CAS  Article  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Yan, M. et al. ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts. Nat. Immunol. (2022).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

ETS1 is a key transcription factor that drives RANKL-expressing, tissue-destructive fibroblasts. Nat Immunol 23, 1303–1304 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing